{
    "clinical_study": {
        "@rank": "90926", 
        "brief_summary": {
            "textblock": "To evaluate the safety, tolerability, and description of time to Pneumocystis carinii\n      pneumonia (PCP) for long-term biweekly administration of 1 of 2 doses of aerosol pentamidine\n      when used as a prophylactic agent in patients who have had one episode of AIDS-associated\n      PCP."
        }, 
        "brief_title": "A Double-Blind Study To Evaluate the Long-Term Safety and Effectiveness of 60 mg Versus 120 mg of Aerosol Pentamidine in the Prophylaxis of Pneumocystis Carinii Pneumonia in AIDS Patients", 
        "condition": [
            "Pneumonia, Pneumocystis Carinii", 
            "HIV Infections"
        ], 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome", 
                "Pneumonia", 
                "Pneumonia, Pneumocystis"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Patients who have completed 16 treatments under Fisons study no. 87-71 entitled, \"A\n        Double-Blind Group Comparative Study To Evaluate the Safety and Effectiveness of Three\n        Different Doses of Aerosol Pentamidine in the Prophylaxis of Pneumocystis Carinii\n        Pneumonia in Patients With AIDS Post First Episode PCP.\" Detailed safety parameters must\n        have been documented for 6 months.\n\n          -  Patients must receive the first dose on this study within 2 weeks of their last dose\n             under study no. 87-71.\n\n        Exclusion Criteria\n\n        Co-existing Condition:\n\n        Patients with the following are excluded:\n\n          -  Requiring ongoing active therapy for an opportunistic infection (O.I.) at time of\n             entry or those patients with either of the following AIDS-defining O.I.'s at entry:\n\n          -  Toxoplasmosis.\n\n          -  Cryptococcosis.\n\n          -  Pulmonary Kaposi's sarcoma.\n\n          -  Asthma poorly controlled by medication.\n\n          -  Receiving active therapy for tuberculosis.\n\n        Patients with the following are excluded:\n\n          -  Requiring ongoing active therapy for an opportunistic infection (O.I.) at time of\n             entry or those patients with either of the following AIDS-defining O.I.'s at entry:\n\n          -  Toxoplasmosis.\n\n          -  Cryptococcosis.\n\n          -  Pulmonary Kaposi's sarcoma.\n\n          -  Unwilling to sign informed consent.\n\n          -  Cannot cooperate with study procedures.\n\n          -  Asthma poorly controlled by medication.\n\n          -  Receiving active therapy for tuberculosis.\n\n        Active substance abuse."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00002054", 
            "org_study_id": "022C", 
            "secondary_id": "87-71 (Part C)"
        }, 
        "intervention": {
            "intervention_name": "Pentamidine isethionate", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Pentamidine"
        }, 
        "keyword": [
            "AIDS-Related Opportunistic Infections", 
            "Pneumonia, Pneumocystis carinii", 
            "Pentamidine", 
            "Dose-Response Relationship, Drug", 
            "Acquired Immunodeficiency Syndrome"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "location": {
            "facility": {
                "address": {
                    "city": "Rochester", 
                    "country": "United States", 
                    "state": "New York", 
                    "zip": "14603"
                }, 
                "name": "Fisons Corp"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "A Double-Blind Study To Evaluate the Long-Term Safety and Effectiveness of 60 mg Versus 120 mg of Aerosol Pentamidine in the Prophylaxis of Pneumocystis Carinii Pneumonia in AIDS Patients", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "N/A", 
        "reference": [
            {
                "citation": "Hogan CH, Hodges JS, Mugglin A, Peterson PM, Abrams DI, Saravolatz L. The perils of visit-driven endpoints in antiretroviral trials. Int Conf AIDS. 1996 Jul 7-12;11(1):237 (abstract no TuB522)"
            }, 
            {
                "citation": "Wulfsohn M, Fischl M, Tsiatis A. Predictors of survival among patients with AIDS receiving zidovudine. Int Conf AIDS. 1992 Jul 19-24;8(2):C314 (abstract no PoC 4419)"
            }, 
            {
                "PMID": "8095980", 
                "citation": "De Gruttola V, Wulfsohn M, Fischl MA, Tsiatis A. Modeling the relationship between survival and CD4 lymphocytes in patients with AIDS and AIDS-related complex. J Acquir Immune Defic Syndr. 1993 Apr;6(4):359-65."
            }, 
            {
                "citation": "Lavelle J, Murphy R, Harding P, Pierce P. Aerosolized pentamidine prophylaxis following Pneumocystis carinii pneumonia in patients with AIDS. Int Conf AIDS. 1990 Jun 20-23;6(2):374 (abstract no 2083)"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00002054"
        }, 
        "source": "NIH AIDS Clinical Trials Information Service", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Fisons", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Masking: Double-Blind, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 1989"
    }, 
    "geocoordinates": {
        "Fisons Corp": "43.161 -77.611"
    }
}